Instil Bio Inc (TIL) USD0.000001

Sell:$17.00Buy:$17.50$0.34 (1.96%)

Prices delayed by at least 15 minutes
Sell:$17.00
Buy:$17.50
Change:$0.34 (1.96%)
Prices delayed by at least 15 minutes
Sell:$17.00
Buy:$17.50
Change:$0.34 (1.96%)
Prices delayed by at least 15 minutes

Company Information

About this company

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.

Key people

Bronson Crouch
Chairman of the Board, Chief Executive Officer
Sandeep Laumas
Chief Financial Officer, Chief Business Officer
Neil W. Gibson
Lead Independent Director
Gwendolyn Knowlton Binder-Scholl
Independent Director
George Matcham
Independent Director
R. Kent Mcgaughy
Independent Director
Click to see more

Key facts

  • EPIC
    TIL
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US45783C2008
  • Market cap
    $117.99m
  • Employees
    14
  • Shares in issue
    6.53m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.